Prothena Corporation plc has provided an overview of its current clinical development programs targeting diseases caused by protein dysregulation. The company highlighted its late-stage pipeline, including prasinezumab, an anti-α-synuclein antibody for Parkinson's disease, which is set to enter Phase 3 trials by the end of 2025 in collaboration with Roche. The pipeline also includes coramitug (PRX004), now fully licensed to Novo Nordisk, in Phase 3 development for transthyretin amyloid cardiomyopathy (ATTR-CM), and BMS-986446 (PRX005), a monoclonal antibody targeting Tau in Alzheimer's disease, currently in Phase 2 trials with results expected in the first half of 2027. Additional programs in neurodegeneration are progressing through early-stage clinical trials. The presentation details the scope and status of these programs, as well as the company's collaborations with partners such as Roche, Bristol Myers Squibb, and Novo Nordisk. You can access the full presentation through the link below.